Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
This is outstanding, they will offer it as an option instead of the standard of care first line treatment. That really says something about what the clinicians think about it.
Across most cancer types, elevated FAP is associated with worse clinical outcomes. This is life changing for the outcome of the patients embarking on the trial. Imagine tumour shrinkage at earlier stages of high FAP cancers. It’s can mean the difference between being able to have life saving surgery or not.
My sister only needed 1cm more shrinkage of her tumour to enable life saving surgery. She had max tolerated dose of dox even though it had worked well (with horrendous side effects) and couldn’t have the life saving surgery. She died months later leaving 4 very young children under the age of ten years. She may have survived much longer or even been able then to have the surgical cure had she been on this trial. She would’ve taken even one more day with her children. This is going to give people a much better chance.
MSK have good results with Doxorubicin and early stage breast cancer in dose-dense chemo regime. With AVA6000 Higher, more frequent doses without chemo side effects is a paradigm shift. It will completely change how we perceive a cancer diagnosis.
https://www.mskcc.org/cancer-care/types/breast/treatment/systemic-therapy/chemotherapy
The question was asked about how it is administered on one of the recordings, AS said in the trials it is administered the same as standard dox is administered IV. Makes sense to compare the two the same way.
He did mention it maybe possible in future to do it bolus but didn’t mention if that was their intention.
Https://www.bbc.co.uk/sounds/play/m001s5nl
Radio 4, Bottom line this morning, for anyone interested, panel having general discussion on biotech drug development and big Pharma acquisitions etc.
thanks es, very interesting. 42 mins in they discuss trial design when gathering substantial clinical data for break through therapy , they mention cohort expansion, optimal dosing and ****genous tumours types. all the same things that al and fiona said in the last video. very interesting.
It might mean the difference between living and dying from your disease. I nearly cried when he confirmed it. My sisters cancer had been reduced 2cm by Dox and although they had given her a terminal diagnosis there was some hope after the dox treatment had worked so well , that they might be able to operate but a scan revealed her cancer had spread and they wouldn’t continue treatment and she died, very young in the most awful manner leaving four young children. Fastest route possible to approval can’t come quickly enough for some.
No 8, “if you believe that your company is planning to merge, or has secretly already agreed to merge, and the announcement might not be for several months, then the resignation of key employees can be seen as bullish.
This is true if you think the employee who resigned would know about the merger, and might also be redundant in the new company.
When companies merge there are cost savings. Supply chains are merged, technology is shared, and many employees are let go. You don’t need two chief financial officers, or two chief medical officers. There will be some redundancy.”
I think it’s telling that Christina is stepping in for an interim period. Perhaps just until the deal is done.
This is very interesting. Ras is referred to currently as undruggable. This could mean that terminal diagnosis as is currently the case with RAS mutations could be a thing of the past.
Dox is dox, big pharma know this. P1a is sufficient for BO of therapeutics. I don’t see how they can hang onto it. Ethically it has to get to patients asap. There will be huge demand. Chemo side effects are horrendous and traumatic, people take years to recover mentally even when recovered from cancer. If you are terminal it’s horrific way to end your days. It’s torture. You lose dignity as well as your life.
Diagnostics will remain with Avacta.